Leboux Romain J T, Schipper Pim, van Capel Toni M M, Kong Lily, van der Maaden Koen, Kros Alexander, Jiskoot Wim, de Jong Esther C, Bouwstra Joke A
Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands.
Front Allergy. 2021 Apr 8;2:642788. doi: 10.3389/falgy.2021.642788. eCollection 2021.
The skin is an attractive alternative administration route for allergy vaccination, as the skin is rich in dendritic cells (DCs) and is easily accessible. In the skin multiple subsets of DCs with distinct roles reside at different depths. In this study antigen (=allergen for allergy) formulations were injected in human skin in a depth-controlled manner by using a hollow microneedle injection system. Biopsies were harvested at the injection site, which were then cultured for 72 h. Subsequently, the crawled-out cells were collected from the medium and analyzed with flow cytometry. Intradermal administration of ovalbumin (OVA, model antigen) solution at various depths in the skin did not affect the migration and maturation of DCs. OVA was taken up efficiently by the DCs, and this was not affected by the injection depth. In contrast, Bet v 1, the major allergen in birch pollen allergy, was barely taken up by dermal DCs (dDCs). Antigens were more efficiently taken up by CD14 dDCs than CD1a dDCs, which in turn were more efficient at taken up antigen than Langerhans cells. Subsequently, both OVA and Bet v 1 were formulated in cationic and anionic liposomes, which altered antigen uptake drastically following intradermal microinjection. While OVA uptake was reduced by formulation in liposomes, Bet v 1 uptake in dDCs was increased by encapsulation in both cationic and anionic liposomes. This highlights the potential use of liposomes as adjuvant in intradermal allergy vaccine delivery. In conclusion, we observed that antigen uptake after intradermal injection was not affected by injection depth, but varied between different antigens and formulation.
皮肤是过敏疫苗接种颇具吸引力的替代给药途径,因为皮肤富含树突状细胞(DCs)且易于触及。在皮肤中,具有不同作用的多个DC亚群位于不同深度。在本研究中,通过使用中空微针注射系统以深度可控的方式将抗原(=过敏症的过敏原)制剂注射到人体皮肤中。在注射部位采集活检组织,然后培养72小时。随后,从培养基中收集爬出的细胞并用流式细胞术进行分析。在皮肤不同深度皮内注射卵清蛋白(OVA,模型抗原)溶液不影响DCs的迁移和成熟。OVA被DCs有效摄取,且这不受注射深度的影响。相比之下,桦树花粉过敏中的主要过敏原Bet v 1几乎不被真皮DCs(dDCs)摄取。抗原被CD14 dDCs摄取的效率高于CD1a dDCs,而CD1a dDCs摄取抗原的效率又高于朗格汉斯细胞。随后,OVA和Bet v 1都被制成阳离子和阴离子脂质体,皮内微注射后抗原摄取发生了显著变化。虽然脂质体制剂使OVA摄取减少,但阳离子和阴离子脂质体包封均使dDCs中Bet v 1的摄取增加。这突出了脂质体作为皮内过敏疫苗递送佐剂的潜在用途。总之,我们观察到皮内注射后抗原摄取不受注射深度影响,但在不同抗原和制剂之间存在差异。